Bhagavati Satyakam
Department of Neurology, SUNY Downstate Medical Center, 450 Clarkson Ave, Brooklyn, New York 11203, USA.
Curr Stem Cell Res Ther. 2008 Sep;3(3):219-28. doi: 10.2174/157488808785740343.
The use of stem cells to repair and replace damaged skeletal muscle cells in chronic, debilitating muscle diseases such as the muscular dystrophies holds great promise. Different stem cell populations, both of embryonic and adult origin display the potential to generate skeletal muscle cells and have been studied in animal models of muscular dystrophy. These include muscle derived satellite cells; bone marrow derived mesenchymal stem cells, muscle or bone marrow side population cells, circulating CD133+ cells and cells derived from blood vessel walls such as mesoangioblasts or pericytes. The design of effective stem cell based therapies requires a detailed understanding of the molecules and signaling pathways which determine myogenic lineage commitment and differentiation. We discuss the great strides that have been made in delineating these pathways and how a better understanding of muscle stem cell biology has the potential to lead to more effective stem cell based therapies for skeletal muscle regeneration for devastating muscle diseases.
利用干细胞修复和替换慢性衰弱性肌肉疾病(如肌营养不良症)中受损的骨骼肌细胞,具有巨大的前景。不同来源的干细胞群体,包括胚胎来源和成年来源的,都显示出产生骨骼肌细胞的潜力,并已在肌营养不良症的动物模型中进行了研究。这些包括肌肉来源的卫星细胞;骨髓来源的间充质干细胞、肌肉或骨髓侧群细胞、循环CD133+细胞以及血管壁来源的细胞,如中血管周细胞或周细胞。基于干细胞的有效疗法的设计需要详细了解决定肌源性谱系定向和分化的分子和信号通路。我们讨论了在描绘这些通路方面取得的巨大进展,以及对肌肉干细胞生物学的更好理解如何有可能为毁灭性肌肉疾病的骨骼肌再生带来更有效的基于干细胞的疗法。